Victory Capital Management
PSTV

Victory Capital Management’s Plus Therapeutics PSTV Stock Holding History

Victory Capital Management’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3
Closed -$2K – 3086
2020
Q1 		$2K Buy
+3
New +$2.31K ﹤0.01% 3664
2019
Q4 		– Hold
0
– – – 3108
2019
Q3 		– Hold
0
– – – 3780

Other funds holding PSTV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
FP
Financial Perspectives Minneapolis, Minnesota $411M AUM 26.27% 1-Year Est. Return

Victory Capital Management's PSTV Position: Q2 2020 in Review

Victory Capital Management sold out of Plus Therapeutics (PSTV) in Q2 2020, closing a stake of 3 shares — an estimated $2K sold.

Victory Capital Management first reported a position in PSTV in Q1 2020 and held it in 1 quarter. The position peaked at $2K in Q1 2020. 5 funds tracked by Wall St. Rank hold PSTV as of Q2 2020.

  • Victory Capital Management reported no remaining Plus Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 3 Plus Therapeutics shares in Q2 2020, an estimated $2K.
  • Victory Capital Management first reported a position in Plus Therapeutics in Q1 2020 and held it in 1 quarter.
  • Victory Capital Management's Plus Therapeutics position peaked at $2K in Q1 2020.
  • 5 funds tracked by Wall St. Rank held Plus Therapeutics as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.